The effects of phenytoin and its major metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH), on bone resorption of neonatal mouse calvaria were examined in vitro. Both phenytoin and HPPH induced significant bone resorption as compared to the controls after 72 h in culture. This effect may be the cause of phenytoin-induced bone loss in vivo.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1254/jjp.82.82 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Yak milk inhibits osteoclast differentiation by suppressing TRPV5 expression.
J Dairy Sci
January 2025
Department of Food Science and Engineering, College of Life Science & Technology, Xinjiang University, Urumqi 830046, China; Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, Xinjiang University, Urumqi 830046, China.
Yak milk is a potential nutrient for improving osteoporosis. However, the effect of yak milk on the expression of Caion channel TRPV5 during osteoclast (OC) differentiation is still unclear. This study used ruthenium red as a control to investigate the effect of yak milk on osteoclast differentiation and activity.
View Article and Find Full Text PDFEffects of low phosphorus diets on phosphorus balance and plasma concentrations of 25-hydroxyvitamin D3, and carboxy-terminal collagen crosslinks during the transition period in dairy cows.
J Dairy Sci
January 2025
Department of Population Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 7, 3584 CL Utrecht, the Netherlands.
Our aim was to determine the effects of P intake on P balance, serum parathyroid hormone (PTH) levels and bone resorption during the final 4 weeks prepartum and the first 8 weeks of lactation. Sixty pregnant multiparous Holstein Friesian dairy cows were assigned to a randomized block design with repeated measurements and dietary treatments arranged according to a 2 × 2 factorial design. The experimental diets contained 3.
View Article and Find Full Text PDFComparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses.
J Bone Miner Res
January 2025
Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima-city, Fukushima, Japan.
This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period.
View Article and Find Full Text PDFClinical efficacy and safety of Tinidazole combined with minocycline in treating peri-implantitis.
Am J Transl Res
December 2024
Department of Stomatology, Hongci Hospital Tangshan 063000, Hebei, China.
Objective: To evaluate the effects of tinidazole (TNZ) combined with minocycline (MINO) on therapeutic effectiveness, bone resorption, and inflammation in peri-implantitis (PI).
Methods: This retrospective study included 96 PI patients admitted between January 2023 and February 2024. Patients were divided into a control group (n = 46) treated with MINO and a research group (n = 50) treated with TNZ plus MINO.
Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study.
Osteoporos Int
January 2025
Kobayakawa Orthopaedics and Rheumatologic Clinic, 1969 Kuno, Fukuroi, Shizuoka, 437-0061, Japan.
Unlabelled: This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers.
Purpose: To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!